PFO
COGT icon

Pathstone Family Office’s Cogent Biosciences COGT Stock Holding History

Pathstone Family Office’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$169K Buy
+17,309
New +$205K ﹤0.01% 1546

Other funds holding COGT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Pathstone Family Office's COGT Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Cogent Biosciences (COGT) in Q3 2023: 17,309 shares worth $169K. The stake represents ﹤0.01% of the portfolio and ranks #1546 among its holdings.

135 funds tracked by Wall St. Rank hold COGT as of Q3 2023.

  • Pathstone Family Office held 17,309 shares of Cogent Biosciences worth $169K as of Q3 2023.
  • Cogent Biosciences was a new Pathstone Family Office position in Q3 2023.
  • Cogent Biosciences made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1546 holding.
  • 135 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.